TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32251060

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ) 162 mg/wk in combination with csDMARDs for 24 weeks
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ) monotherapy continued until week 52 for patients who achieved remission at week 24
Number of subjects: 284

Group type: COMPARATOR
Intervention: Combination therapy with csDMARDs
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adverse events during follow-up
Number of subjects: 284
Study: 32251621

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 1: PD-L1 expression at least 1%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 2: PD-L1 less than 1% or unevaluable)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 42
Study: 32251757

Group type: EXPERIMENTAL
Intervention: Parametric Response Mapping (PRM) using coregistered PET and DCE CT imaging
Number of subjects: 21

Group type: COMPARATOR
Intervention: Concurrent chemoradiation therapy
Number of subjects: 21
Study: 32252538

Group type: EXPERIMENTAL
Intervention: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) - 50 iTBS sessions, 1,800 pulses per session, delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Neuropsychological testing before and after SAINT.
Number of subjects: 22
Study: 32252696

Group type: EXPERIMENTAL
Intervention: Simplified method of scoring the Core Conflictual Relationship Theme (CCRT) based on live semi-structured dynamic interviews without transcribing material.
Number of subjects: 52
Study: 32252720

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD, duration: 90 days, targeted at the left dorsolateral prefrontal cortex.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Wait-list group (n=10) as a comparison.
Number of subjects: 87
Study: 32252752

Group type: EXPERIMENTAL
Intervention: Surgery for SBO
Number of subjects: 402
Study: 32252781

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (modern radiotherapy techniques: intensity-modulated or volumetric modulated arc radiotherapy)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy alone or in combination with chemotherapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (radiotherapy or chemotherapy)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 161
Study: 32252809

Group type: EXPERIMENTAL
Intervention: Interferon-regulated gene score (IRG-S) in JDM patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon-regulated gene score (IRG-S) in anti-MDA5 autoantibody-positive JDM patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Individual gene contributions to IRG-S
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Correlation of IRG-S with disease activity measures
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of IRG-S between JDM and CANDLE/SAVI
Number of subjects: 57
Study: 32253717

Group type: EXPERIMENTAL
Intervention: Conivaptan (20 mg) administered every 12 hours for 2 days along with standard ICH management
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard ICH management
Number of subjects: 7
Study: 32254044

Group type: EXPERIMENTAL
Intervention: Wearable device intervention with personalized goal-setting and financial incentives
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 99
Study: 32256049

Group type: EXPERIMENTAL
Intervention: Camrelizumab 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks (dose-escalation phase)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg or 600 mg every 4 weeks (dose-expansion phase)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Camrelizumab (all doses)
Number of subjects: 49
Study: 32256115

Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of acalabrutinib and obinutuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acalabrutinib
Number of subjects: 0
Study: 32256270

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine plus 200 mg chlorogenic acid (CFCA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine plus 200 mg placebo (starch) (CFPL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 200 mg chlorogenic acid plus 200 mg placebo (CAPL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 200 mg placebo plus 200 mg placebo (PLPL)
Number of subjects: 26
Study: 32256610

Group type: EXPERIMENTAL
Intervention: Deciduous dental pulp stem cells (DDPSC) associated with hydroxyapatite-collagen sponge (Bio-Oss Collagen® 250 mg, Geistlich)
Number of subjects: 6

Group type: COMPARATOR
Intervention: rhBMP-2
Number of subjects: 6

Group type: COMPARATOR
Intervention: iliac crest bone graft
Number of subjects: 6
Study: 32256673

Group type: EXPERIMENTAL
Intervention: Higher serum choline levels (T3)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Serum betaine levels
Number of subjects: 866
Study: 32256757

Group type: EXPERIMENTAL
Intervention: Uniblocker
Number of subjects: 60

Group type: COMPARATOR
Intervention: Left-sided double-lumen tube (LDLT)
Number of subjects: 60
Study: 32258217

Group type: EXPERIMENTAL
Intervention: rAAV-DJ-S269T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rAAV-LK03-Y705+731F
Number of subjects: 0

Group type: COMPARATOR
Intervention: rAAV-DJ
Number of subjects: 0

Group type: COMPARATOR
Intervention: rAAV-LK03
Number of subjects: 0
Study: 32258361

Group type: EXPERIMENTAL
Intervention: Large scaffold diameter (LScD, ≥3 mm)
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Small scaffold diameter (SScD, 2.5 mm)
Number of subjects: 1785
Study: 32258443

Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning (PBS)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Passive Scatter/Uniform Scanning (PS/US)
Number of subjects: 304
Study: 32258591

Group type: EXPERIMENTAL
Intervention: Oculomotor and gaze stability exercises applied at home twice a day for three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current rehabilitation program
Number of subjects: 0
Study: 32258819

Group type: EXPERIMENTAL
Intervention: Covariate-constrained randomization algorithm applied in waves (2-8 facilities/wave) from June 2017 to March 2019.
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Arm 2 allocated more nursing homes with severely cognitive impaired residents above the median.
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Covariate-constrained randomization algorithm.
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Original randomization scheme for TRAIN-AD.
Number of subjects: 424
Study: 32258956

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone enanthate weekly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32258987

Group type: EXPERIMENTAL
Intervention: List-based method for measuring food group indicators (FGIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open recall method for measuring food group indicators (FGIs)
Number of subjects: 0
Study: 32258995

Group type: EXPERIMENTAL
Intervention: Revised CACFP meal patterns
Number of subjects: 0
Study: 32258996

Group type: EXPERIMENTAL
Intervention: Teacher intervention-only programs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Teacher and classroom training programs
Number of subjects: 9
Study: 32259077

Group type: EXPERIMENTAL
Intervention: Ralaniten (EPI-002)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPI-045 (analogue of ralaniten)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucuronidated metabolites of ralaniten
Number of subjects: 0
Study: 32259257

Group type: EXPERIMENTAL
Intervention: High-risk ECG score
Number of subjects: 7362

Group type: EXPERIMENTAL
Intervention: Low-risk ECG score
Number of subjects: 7362

Group type: COMPARATOR
Intervention: ECG markers added to clinical risk factor model
Number of subjects: 7362
Study: 32259334

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (Kovaltry) prophylaxis, infused ≥3×/wk (59% of patients)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (Kovaltry) prophylaxis
Number of subjects: 160
Study: 32259825

Group type: EXPERIMENTAL
Intervention: AD8 (Ascertain Dementia 8)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CDR (Clinical Dementia Rating Scale)
Number of subjects: 75
Study: 32264716

Group type: EXPERIMENTAL
Intervention: 2-lead Optimizer system
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3-lead Optimizer system
Number of subjects: 60
Study: 32264715

Group type: EXPERIMENTAL
Intervention: iVAS therapy
Number of subjects: 47
Study: 32264726

Group type: EXPERIMENTAL
Intervention: FF-10501-01 (IMPDH inhibitor)
Number of subjects: 38
Study: 32264845

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Implicit measures (not specified)
Number of subjects: 67
Study: 32264848

Group type: EXPERIMENTAL
Intervention: Alcohol marketing exposure
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Demarketing intervention
Number of subjects: 720
Study: 32264969

Group type: EXPERIMENTAL
Intervention: Opportunistic infections (OI)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Serious/severe/very severe non-OI
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Total infections adjudicated
Number of subjects: 572
Study: 32265584

Group type: EXPERIMENTAL
Intervention: Bupivacaine and dexmedetomidine (group D)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bupivacaine and magnesium sulfate (group M)
Number of subjects: 52
Study: 32265627

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of autologous bone marrow mononuclear cells (BMMCs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 22
Study: 32266070

Group type: EXPERIMENTAL
Intervention: Emotion regulation group skills training
Number of subjects: 29
Study: 32266327

Group type: EXPERIMENTAL
Intervention: Gender equity focused family planning program
Number of subjects: 0
Study: 32266379

Group type: EXPERIMENTAL
Intervention: Eccentric strength training of the spastic muscles for 6 weeks
Number of subjects: 6
Study: 32266602

Group type: COMPARATOR
Intervention: Septic patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-survivors
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Retinal arteriolar vessels
Number of subjects: 48
Study: 32266800

Group type: COMPARATOR
Intervention: Endometrial aspiration biopsy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dilatation and curettage (D&C)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Progestin treatment regimens (oral medroxyprogesterone acetate (MPA) 10 mg/day for 14 days per cycle, continuous MPA 10 mg/day, levonorgestrel-releasing intrauterine system (LNG-IUS))
Number of subjects: 65
Study: 32267227

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) treatment at a fixed 75% degree of maximal protrusion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Position of the soft palate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Crowding of the oropharynx
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posteriorly located soft palate with MAD in situ
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posteriorly located tongue base with MAD in situ
Number of subjects: 100
Study: 32267734

Group type: EXPERIMENTAL
Intervention: Autologous freshly isolated primary chondrocytes and bone marrow mononucleated cells (MNCs) seeded into a PolyActive scaffold
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Autologous freshly isolated primary chondrocytes and bone marrow MNCs
Number of subjects: 40
Study: 32267881

Group type: EXPERIMENTAL
Intervention: Environmental and spatial determinants of enteric pathogen infection
Number of subjects: 0
Study: 32267967

Group type: EXPERIMENTAL
Intervention: EE4A chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study: 32268350

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 129
Study: 32268367

Group type: EXPERIMENTAL
Intervention: AKCEA-APO(a)-LRx
Number of subjects: 32

Group type: COMPARATOR
Intervention: PCSK9ab
Number of subjects: 32
Study: 32268821

Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg and 40 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Leflunomide (60 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Leflunomide (all doses)
Number of subjects: 11
Study: 32268996

Group type: COMPARATOR
Intervention: Control participants in the Centering Pregnancy Plus Project (2008-2012)
Number of subjects: 623
Study: 32269016

Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography
Number of subjects: 544

Group type: COMPARATOR
Intervention: Conventional echocardiography
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Cardiac assessment including medical history, physical examination, anthropometry, vital parameters, 1-minute sit-to-stand test, echocardiography
Number of subjects: 544
Study: 32269053

Group type: EXPERIMENTAL
Intervention: Repotrectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 32269051

Group type: EXPERIMENTAL
Intervention: GDC-0084
Number of subjects: 47
Study: 32269131

Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 5799

Group type: COMPARATOR
Intervention: EDACS
Number of subjects: 5799
Study: 32269142

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN-γ) combined with high-dose cyclophosphamide (HD Cy) and low-dose interleukin (IL)-2.
Number of subjects: 2
Study: 32269146

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PROSTVAC vaccine
Number of subjects: 27
Study: 32269549

Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Nerve Sensory Stimulation and Motor Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32270053

Group type: EXPERIMENTAL
Intervention: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once-daily for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: simeprevir, daclatasvir, and sofosbuvir
Number of subjects: 40
Study: 32270056

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir once-daily for 12 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Xpert HCV VL Fingerstick assay
Number of subjects: 32
Study: 32270133

Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Number of subjects: 30
Study: 32270264

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) for 8 hours at terrestrial altitude 3840 m
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normobaric hypoxia (NH) for 8 hours
Number of subjects: 16
Study: 32270313

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 327 MBq (range 299-399 MBq) of folate receptor alpha-targeted agent
Number of subjects: 6
Study: 32270710

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study: 32271073

Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT)
Number of subjects: 10
Study: 32271149

Group type: EXPERIMENTAL
Intervention: mHealth Fit After Baby program
Number of subjects: 26
Study: 32271247

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS) implantation in calcified coronary lesions
Number of subjects: 3326
Study: 32271353

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 20
Study: 32271464

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32271898

Group type: EXPERIMENTAL
Intervention: tisagenlecleucel
Number of subjects: 111
Study: 32271899

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion with tocilizumab
Number of subjects: 111
Study: 32271900

Group type: EXPERIMENTAL
Intervention: Bendamustine and rituximab (BR)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 1494

Group type: COMPARATOR
Intervention: BR or FCR
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1494
Study: 32272105

Group type: EXPERIMENTAL
Intervention: 2-Minute Walk Test (2-MWT)
Number of subjects: 101
Study: 32272183

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with CTVp1 (60 Gy in 30 fractions)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with CTVp2 (54 Gy in 30 fractions)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with CTVp1 and CTVp2
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 103
Study: 32272514

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50mg subcutaneous (SC) twice weekly for 12 weeks, followed by ETN 50mg SC once weekly for an additional 12 weeks.
Number of subjects: 80
Study: 32272921

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid/long-acting β agonist (ICS/LABA)
Number of subjects: 4491

Group type: EXPERIMENTAL
Intervention: LTRA added to ICS/LABA
Number of subjects: 4491

Group type: COMPARATOR
Intervention: 2012 vs 2018 GINA criteria
Number of subjects: 4491
Study: 32273027

Group type: EXPERIMENTAL
Intervention: 2-dimensional vascular ultrasound (2DVUS)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: 3-dimensional vascular ultrasound (3DVUS)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Overall progression
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: New atherosclerosis onset
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Participants with baseline disease (n=432)
Number of subjects: 3514
Study: 32273098

Group type: EXPERIMENTAL
Intervention: Emblok embolic protection system
Number of subjects: 20
Study: 32273272

Group type: EXPERIMENTAL
Intervention: Transient neonatal diabetes mellitus (TNDM) participants
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: TNDM participants
Number of subjects: 27

Group type: COMPARATOR
Intervention: Relatives of TNDM participants
Number of subjects: 27
Study: 32273476

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1, cytarabine 2x2g/m2; day 2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) combined with DHAP
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with DHAP
Number of subjects: 55
Study: 32274381

Group type: EXPERIMENTAL
Intervention: YH4808 (potassium-competitive acid blocker); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin and clarithromycin; specific dosages and duration not mentioned.
Number of subjects: 0
Study: 32274380

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of gemigliptin/metformin sustained release 25/500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loose combination of gemigliptin 50 mg and metformin extended release (XR) 500 mg
Number of subjects: 0
Study: 32274878

Group type: EXPERIMENTAL
Intervention: Home monitoring of potassium, creatinine, and estimated plasma volume (ePV) 5 days a week using an approved home-based device (ABOTT i-STAT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Home monitoring of potassium, creatinine, and estimated plasma volume (ePV) 5 days a week
Number of subjects: 15
Study: 32274897

Group type: EXPERIMENTAL
Intervention: Overfeeding (additional 600 kcal, 30 g protein, 72 g carbohydrate, and 21 g fat) in CTs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overfeeding in CTs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (normal-weight individuals)
Number of subjects: 34
Study: 32275314

Group type: EXPERIMENTAL
Intervention: Leucine (Leu) concentrations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Change in Leu from early to late pregnancy (LeuLP-EP)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Metabolic clearance rate (MCR) of glucose
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: HOMA2-IR
Number of subjects: 53
Study: 32275867

Group type: EXPERIMENTAL
Intervention: SJ733 (150 mg dose cohort)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg dose cohort)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SJ733 (various doses: 75, 150, 300, 600, 900, 1200 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SJ733
Number of subjects: 40
Study: 32276015

Group type: EXPERIMENTAL
Intervention: PQ Bypass DETOUR System
Number of subjects: 78
Study: 32277009

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medications washout
Number of subjects: 120
Study: 32277401

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Dulaglutide (both doses)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Glimepiride or Insulin glargine
Number of subjects: 1147
Study: 32278118

Group type: EXPERIMENTAL
Intervention: Phosphorus additive enhanced diet with supplemental calcium (experimental diet) for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Run-in control diet for 2 weeks
Number of subjects: 0